CD47 and cancer: Modulation of CSCs markers, particularly CD47, directly by 4Mu or indirectly through the induction of M1 hepatic Mφ generated by 4Mu could be considered as an approach to sensitize cancer cells to TKI therapy, particularly in patients who have been previously treated with sorafenib.